8-K: Patterson Companies to be Acquired by Patient Square Capital in $4.1 Billion Deal

Patterson Companies has agreed to be acquired by Patient Square Capital for $31.35 per share in cash, valuing the company at approximately $4.1 billion.

Summary

• Patterson Companies, a leading dental and animal health distributor, has entered into a definitive agreement to be acquired by Patient Square Capital.
• The acquisition price is $31.35 per share in cash, representing a 49% premium to the 30-day volume-weighted average price ending December 4, 2024.
• The total transaction value is approximately $4.1 billion, including the refinancing of Patterson's receivables facilities.
• The transaction is expected to close in the fourth quarter of Patterson's fiscal year 2025.
• The deal is subject to shareholder and regulatory approvals, as well as other customary closing conditions.
• Patient Square Capital will finance the acquisition through a combination of equity and debt financing.
• Patterson will become a privately held company upon completion of the transaction and will maintain its headquarters in St. Paul, Minnesota.
• The agreement includes a 40-day go-shop period allowing Patterson to solicit alternative acquisition proposals.

Sentiment

Score: 8

Explanation: The document conveys a positive sentiment due to the significant premium offered to shareholders and the strategic partnership with Patient Square Capital. The language used by management is optimistic, and the deal is presented as a positive step for the company's future.

Positives

• The acquisition provides immediate and certain value for Patterson shareholders.
• The transaction allows Patterson to continue investing in serving its customers and driving growth.
• Patient Square Capital shares a long-term vision for Patterson and is considered an excellent partner.
• The deal includes a go-shop period, allowing for potential alternative offers.

Negatives

• Patterson will become a privately held company, and its stock will no longer be traded on the NASDAQ.
• The transaction is subject to shareholder and regulatory approvals, which could potentially delay or prevent the deal from closing.

Risks

• The inability to consummate the merger within the anticipated time period, or at all, due to various reasons, including failure to obtain required approvals or complete financing.
• The risk that the merger disrupts current plans and operations or diverts management's attention.
• Potential negative effects of the merger on the business, operating results, and ability to retain key personnel and maintain relationships.
• The risk that the stock price may decline significantly if the merger is not consummated.
• The nature, cost, and outcome of any legal proceedings related to the merger.
• Dependence on suppliers, potential disruption of distribution, and risks associated with private label products.
• Risks related to technology, innovation, reputation, illicit use of pharmaceuticals, acquisitions, personnel, information systems, cybersecurity, artificial intelligence, public health concerns, climate change, and compliance with laws and regulations.
• Exposure to the risks of the animal production and companion animal businesses, and the healthcare industry.

Future Outlook

The transaction is expected to close in the fourth quarter of Patterson's fiscal 2025, subject to shareholder and regulatory approvals and other customary closing conditions. Patterson will become a privately held company upon completion of the transaction.

Management Comments

• Don Zurbay, President and Chief Executive Officer of Patterson, stated that the transaction delivers immediate and certain value for shareholders and positions the company to continue to invest in serving customers and driving growth.
• Jim Momtazee, Managing Partner at Patient Square, expressed admiration for Patterson and excitement to work with management on the next chapter of growth.

Industry Context

This acquisition reflects the ongoing consolidation trend in the healthcare distribution sector, with private equity firms increasingly seeking to invest in established companies with strong market positions. The deal also highlights the continued interest in both the dental and animal health markets.

Comparison to Industry Standards

• The 49% premium offered to Patterson shareholders is significant, suggesting a competitive bidding process or a strong desire by Patient Square to acquire the company.
• The use of a combination of equity and debt financing is typical for large private equity acquisitions.
• The inclusion of a go-shop period is a common practice in such transactions, allowing the company to explore other potential offers.
• The transaction value of $4.1 billion is substantial, placing Patterson among the larger deals in the healthcare distribution space.
• Comparable transactions in the healthcare distribution sector have seen similar premiums and financing structures, though specific details vary based on the target company's financials and market position.

Stakeholder Impact

• Shareholders will receive a significant premium for their shares.
• Employees will continue to be employed by the surviving company.
• Customers and suppliers will continue to have relationships with Patterson.
• Creditors will be repaid as part of the transaction.

Next Steps

• Patterson will prepare and file a proxy statement with the SEC.
• A special shareholder meeting will be held to vote on the adoption and approval of the merger agreement.
• The parties will seek regulatory approvals.
• The transaction is expected to close in the fourth quarter of Patterson's fiscal 2025.

Key Dates

Keywords

acquisition, merger, Patterson Companies, Patient Square Capital, dental distribution, animal health distribution, private equity, go-shop, takeover, healthcare investment